Search Medical Condition
Please enter condition
Please choose location from dropdown

Pulmonary Arterial Hypertension Clinical Trials

A listing of Pulmonary Arterial Hypertension medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (103) clinical trials

The primary objective of this study is to assess the effect of oral treprostinil compared with placebo on change in exercise capacity as measured by change in 6MWD from Baseline to Week 24 in subjects with PH associated with HFpEF. There are no approved treatments for PH in subjects with ...

Phase

Researchers at the University of Kentucky are conducting a study to investigate the safety and how well the inhaled investigational drug treprostinil works in people with pulmonary hypertension associated with lung disease. This study will look at your ability to exercise after taking the study drug. You may be eligible ...

Phase N/A

NYU Winthrop Hospital Clinical Trials Center is conducting this clinical research study for patients between the ages of 18 and 85 years old, who have been diagnosed with PAH. Pulmonary Arterial Hypertension occurs when the pressure in the pulmonary artery (the blood vessel that leads from the heart to the ...

Phase N/A

People with Pulmonary Arterial Hypertension are asked to participate in a research study being conducted by North Shore University Hospital.

Phase N/A

This is a multicenter, randomized (1:1; oral treprostinil to placebo), double-blind, placebo-controlled study in subjects with World Health Organization (WHO) Group 2 pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF). Once randomized, subjects will take the initial dose of study drug at the study site on ...

Phase

The purpose of this study is to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects  

Phase

ABI-009 an mTOR Inhibitor for Patients With Severe Pulmonary Arterial Hypertension

mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models. ABI-009 is an albumin-bound mTOR inhibitor with improved penetration in lung tissue.

Phase

Revavtio Special Investigation for Long-term Use in Pediatric Patients

The objective of this study is to obtain the information on dosage and administration, safety, and efficacy of Revatio when it is administered for a long period of time (1 year) under the actual use after the approval of the dosage and administration in pediatric patients (aged 1 year or ...

Phase N/A

Pulmonary Vascular Disease Phenomics Program PVDOMICS

The protocol is designed to lead to new understanding of patients with pulmonary hypertension and right heart dysfunction, based on molecular, clinical, hemodynamic and radiographic characteristics. New classifications will be a product of association of these in depth phenotypic descriptions with specific molecular mechanisms of pathogenesis. The protocol will be ...

Phase N/A

ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy

Patients with IPAH, HPAH, PAH-CTD and PAH-HIV meeting all inclusion and no exclusion criteria will be enrolled. An open label phase 1a study (evaluating dosage and safety) will be conducted. This will followed by a randomized double blind placebo controlled Phase 1b study after Data Safety and Monitoring Board (DSMB) ...

Phase